Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
1.6800 x 2 1.7000 x 1
Post-market by (Cboe BZX)
1.6900 +0.0100 (+0.60%) 04/23/25 [NASDAQ]
1.6800 x 2 1.7000 x 1
Post-market 1.6800 -0.0100 (-0.59%) 17:28 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.6600
Day High
1.7300
Open 1.7200
Previous Close 1.6800 1.6800
Volume 53,200 53,200
Avg Vol 122,090 122,090
Stochastic %K 51.72% 51.72%
Weighted Alpha -92.56 -92.56
5-Day Change -0.1300 (-7.14%) -0.1300 (-7.14%)
52-Week Range 1.2900 - 47.8400 1.2900 - 47.8400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,216
  • Shares Outstanding, K 5,486
  • Annual Sales, $ 2,270 K
  • Annual Income, $ -59,600 K
  • EBIT $ -67 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.64
  • Price/Sales 4.14
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 102.52%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 841.79% on 11/19/24
  • IV Low 0.00% on 04/22/25
  • Put/Call Vol Ratio 0.67
  • Today's Volume 25
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 4,394
  • Open Int (30-Day) 4,395

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -2.72
  • Number of Estimates 1
  • High Estimate -2.72
  • Low Estimate -2.72
  • Prior Year -13.92
  • Growth Rate Est. (year over year) +80.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2900 +31.01%
on 04/07/25
Period Open: 2.3300
2.3700 -28.69%
on 03/27/25
-0.6400 (-27.47%)
since 03/21/25
3-Month
1.2900 +31.01%
on 04/07/25
Period Open: 6.0768
6.9920 -75.83%
on 01/24/25
-4.3868 (-72.19%)
since 01/23/25
52-Week
1.2900 +31.01%
on 04/07/25
Period Open: 47.5200
47.8400 -96.47%
on 04/24/24
-45.8300 (-96.44%)
since 04/23/24

Most Recent Stories

More News
WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market

/CNW/ -- Equity Insider News Commentary – The potential for artificial intelligence (AI) in healthcare is still unfolding, both for patients and providers. A...

AVAI : 0.3603 (-2.62%)
AMST : 2.05 (-1.91%)
BTAI : 1.6900 (+0.60%)
TVGN : 1.0200 (+5.15%)
PLTR : 100.82 (+7.27%)
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

BTAI : 1.6900 (+0.60%)
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BTAI : 1.6900 (+0.60%)
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BTAI : 1.6900 (+0.60%)
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BTAI : 1.6900 (+0.60%)
Unbelievable Stock Gains! Why these 7 Micro, Small, and Mid-Cap Stocks Skyrocketed This Week!

Source: Shutterstock The U.S. stock market has taken a significant hit, marking one of the biggest declines in recent times. All major indices are down, largely due to economic uncertainties, including...

PRCH : 5.11 (+4.82%)
BTAI : 1.6900 (+0.60%)
MPW : 5.33 (+2.50%)
TRNR : 0.7753 (-4.43%)
OMI : 6.65 (+2.78%)
HURN : 137.21 (+1.35%)
ORGO : 4.45 (+2.77%)
ZI : 8.23 (+3.65%)
BioXcel Therapeutics Announces $14 Million Registered Direct Offering

BTAI : 1.6900 (+0.60%)
BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

BTAI : 1.6900 (+0.60%)
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BTAI : 1.6900 (+0.60%)
BioXcel Therapeutics Announces Reverse Stock Split

BTAI : 1.6900 (+0.60%)

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

3rd Resistance Point 1.8100
2nd Resistance Point 1.7700
1st Resistance Point 1.7300
Last Price 1.6900
1st Support Level 1.6500
2nd Support Level 1.6100
3rd Support Level 1.5700

See More

52-Week High 47.8400
Fibonacci 61.8% 30.0579
Fibonacci 50% 24.5650
Fibonacci 38.2% 19.0721
Last Price 1.6900
52-Week Low 1.2900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective